SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biogen
BIIB 177.82+1.0%Jan 2 9:30 AM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Luke who wrote (1099)8/16/1999 7:56:00 PM
From: P.M.Freedman  Read Replies (1) of 1686
 
The European patent issue won't hurt BGEN too much. It will only add some European competitors to make similar drugs. It will have to take additional three years to get the new drug analogs to be approved. However, the old US patent law suit with Berlex Lab may become a key issue for BGEN in the bear future. The case has been being active since July 1996. Another hearing has been scheduled in the coming November and the final trial of the case will be in Feb. of next year. If lose, the company will have to pay Berlex for the damage. I am expecting a settlement between the two parties before the final trial. BGEN may not be willing to take the risk of losing the case. However, the future earnings may be affected surely. How much? It will be fully depending on the settlement. Good luck!
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News